Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen J Blake

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
British Journal of Cancer|August 10, 2023
Advancing translational research for colorectal immuno-oncologyElaine M Thomas, Josephine A Wright, Stephen J Blake, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapyCelia Jacoberger-Foissac, Stephen J Blake, Jing Liu, et al.
Immunology and Cell Biology|November 13, 2013
In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV-driven tumoursNorliana Khairuddin, Stephen J Blake, Farah Firdaus, et al.
Experimental Hematology|December 6, 2008
Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivoCara K Fraser, Stephen J Blake, Kerrilyn R Diener, et al.
Immunology and Cell Biology|March 23, 2011
siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivoNorliana Khairuddin, Michael P Gantier, Stephen J Blake, et al.
Cancer Research|September 17, 2016
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich TumorShin Foong Ngiow, Arabella Young, Stephen J Blake, et al.
Cancer Research|August 10, 2016
Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of CancerJing Liu, Stephen J Blake, Heidi Harjunpää, et al.
Cancer Discovery|September 25, 2016
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic DiseaseJing Liu, Stephen J Blake, Michelle C R Yong, et al.
Cancer Cell|September 14, 2016
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune ResponsesArabella Young, Shin Foong Ngiow, Deborah S Barkauskas, et al.
Oncoimmunology|June 15, 2018
Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasisHeidi Harjunpää, Stephen J Blake, Elizabeth Ahern, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|August 10, 2023
Advancing translational research for colorectal immuno-oncologyElaine M Thomas, Josephine A Wright, Stephen J Blake, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapyCelia Jacoberger-Foissac, Stephen J Blake, Jing Liu, et al.
Immunology and Cell Biology|November 13, 2013
In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV-driven tumoursNorliana Khairuddin, Stephen J Blake, Farah Firdaus, et al.
Experimental Hematology|December 6, 2008
Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivoCara K Fraser, Stephen J Blake, Kerrilyn R Diener, et al.
Immunology and Cell Biology|March 23, 2011
siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivoNorliana Khairuddin, Michael P Gantier, Stephen J Blake, et al.
Cancer Research|September 17, 2016
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich TumorShin Foong Ngiow, Arabella Young, Stephen J Blake, et al.
Cancer Research|August 10, 2016
Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of CancerJing Liu, Stephen J Blake, Heidi Harjunpää, et al.
Cancer Discovery|September 25, 2016
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic DiseaseJing Liu, Stephen J Blake, Michelle C R Yong, et al.
Cancer Cell|September 14, 2016
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune ResponsesArabella Young, Shin Foong Ngiow, Deborah S Barkauskas, et al.
Oncoimmunology|June 15, 2018
Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasisHeidi Harjunpää, Stephen J Blake, Elizabeth Ahern, et al.
Pageof 4